Thu, August 12, 2010
Wed, August 11, 2010
Tue, August 10, 2010
Mon, August 9, 2010
Fri, August 6, 2010
Thu, August 5, 2010
Wed, August 4, 2010
Tue, August 3, 2010
Mon, August 2, 2010
Fri, July 30, 2010
Thu, July 29, 2010
Wed, July 28, 2010
Tue, July 27, 2010
Mon, July 26, 2010
Fri, July 23, 2010
Thu, July 22, 2010

AVEO Pharmaceuticals to Present at Cancer Stem Cells & The Tumor Microenvironment Conference


//health-fitness.news-articles.net/content/2010/ .. cells-the-tumor-microenvironment-conference.html
Published in Health and Fitness on Monday, August 2nd 2010 at 4:31 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Murray Robinson, Ph.D., senior vice president, translational medicine, is scheduled to present at the Cancer Stem Cells & The Tumor Microenvironment Conference, part of IBCa™s Drug Discovery & Development Week, on Monday, August 2, 2010 at 1:45 p.m. (PDT) at the Hyatt Regency San Francisco Airport in San Francisco.

"Myeloid Resistance Biomarkers for the VEGFR TKI Tivozanib Identified Using Next Generation Tumor Models"

Dr. Robinson will give a presentation, entitled aMyeloid Resistance Biomarkers for the VEGFR TKI Tivozanib Identified Using Next Generation Tumor Models,a that will focus on the utility of AVEOa™s specific myeloid based multi-gene and IHC resistance biomarkers in assessing the activity of tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, in human renal cell carcinoma (RCC).

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) blends a proprietary cancer biology platform with drug development and commercial expertise to discover and develop targeted cancer therapeutics. The companya™s lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEOa™s proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets includingHGF, ErbB3, RON, Notch andFGFR. For more information, please visit the company's website at [ www.aveopharma.com ].


Publication Contributing Sources